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Abstract  33 
We previously identified FOXL2 as a critical component in FSH gene transcription. Here, we show that 34 
mice deficient in FOXL2 have lower levels of gonadotropin gene expression and fewer LH- and FSH-35 
containing cells, but the same level of other pituitary hormones compared to wild-type littermates, 36 
highlighting a role of FOXL2 in the pituitary gonadotrope. Further, we investigate the function of FOXL2 37 
in the gonadotrope cell and determine which domains of the FOXL2 protein are necessary for induction 38 
of FSHtranscription. There is a stronger induction of FSH reporter transcription by truncated FOXL2 39 
proteins, but no induction with the mutant lacking the forkhead domain. Specifically, FOXL2 plays a role 40 
in activin induction of FSH, functioning in concert with activin-induced SMAD proteins. Activin acts 41 
through multiple promoter elements to induce FSH expression, some of which bind FOXL2. Each of 42 
these FOXL2-binding sites is either juxtaposed or overlapping with a SMAD-binding element. We 43 
determined that FOXL2 and SMAD4 proteins form a higher order complex on the most proximal FOXL2 44 
site. Surprisingly, two other sites important for activin induction bind neither SMADs nor FOXL2, 45 
suggesting additional factors at work. Furthermore, we show that FOXL2 plays a role in synergistic 46 
induction of FSH by GnRH and activin through interactions with the cJUN component of the AP1 47 
complex that is necessary for GnRH responsiveness. Collectively, our results demonstrate the necessity of 48 
FOXL2 for proper FSH production in mice and implicate FOXL2 in integration of transcription factors at 49 
the level of the FSH promoter. 50 
  51 
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Introduction 52 
 53 
Follicle-stimulating hormone (FSH), secreted by the pituitary gonadotrope, is necessary for 54 
mammalian reproductive fitness. Its concentration is tightly regulated, fluctuating only 2-3 fold during the 55 
course of the menstrual or estrous cycle (1, 2). Both excess and deficiency of FSH cause reproductive 56 
problems in females. Low FSH levels impede follicular growth, while high levels are associated with 57 
premature ovarian failure (3). Since FSH can be secreted constitutively, the major regulatory step 58 
controlling its concentration in the circulation is at the transcriptional level. FSH is a heterodimer of a 59 
common -glycoprotein subunit (GSU) and a unique -subunit. In addition to providing biological 60 
specificity, -subunit gene expression is the limiting factor in FSH synthesis. FSH -subunit gene 61 
transcription is induced primarily by GnRH and activin (4-6). GnRH and activin, in addition to having 62 
independent transcriptional effects on the FSHpromoter, interact and cause higher than additive, 63 
synergistic induction, which is specific for FSH, and is postulated to contribute to differential regulation 64 
of the gonadotropin subunits (7). 65 
Activin plays an important role in the regulation of FSH concentration, increasing the release of 66 
FSH from the pituitary (8) and inducing FSHβ gene expression in gonadotrope cells (6). Following 67 
binding and activation of its receptor, activin phosphorylates SMAD2 and SMAD3. In particular, 68 
phosphorylated SMAD3 binds to SMAD4 and translocates into the nucleus to activate transcription of 69 
mouse FSH, by binding the consensus site located at -267 in the mouse FSHβ promoter (9-11). 70 
However, this site does not account for complete activin responsiveness of the rodent promoter (7, 12), 71 
raising the question of what additional binding elements contribute to induction of FSH by activin. 72 
 Further analysis of the regulation of the FSHβ promoter demonstrated that FOXL2 is essential for 73 
activin responsiveness (13-15). FOXL2 is a member of the forkhead family of transcription factors, which 74 
share a conserved DNA-binding domain (16). FOXL2 is expressed in gonadotrope cells (17, 18) and 75 
mediates activin induction of the FSH gene, through several forkhead sites in the proximal mouse FSH 76 
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promoter (14, 15). Additionally, FOXL2 protein has been shown to cooperate with either SMAD3 or 77 
SMAD4 to induce this gene (14, 15, 19, 20). However, it has not been determined which of the additional 78 
activin-responsive sites in the promoter, besides the forkhead sites, are also FOXL2-dependent sites, and 79 
which are SMADs sites or other, as yet unidentified, activin-inducible elements. In addition to FSH, 80 
FOXL2 augments transcription of both follistatin and GnRH receptor in the gonadotrope (17, 18, 21). Of 81 
interest to our investigation, FOXL2-mediated induction of these genes is dependent on SMAD sites 82 
adjacent to the forkhead elements, with FOXL2 functioning in complex with SMAD3. Yet, it is not 83 
known if interaction with SMAD3 activates FOXL2 or whether activin can directly activate FOXL2 via 84 
non-SMAD signaling pathways.  85 
Besides the pituitary, FOXL2 has an important reproductive role in the ovary as well, particularly 86 
in granulosa cell proliferation and differentiation. FOXL2 functions as a transcriptional repressor of 87 
several key genes involved in steroidogenesis (22, 23). Evidence that FOXL2 negatively regulates 88 
SMAD3-dependent, GDF9, and activin-stimulated follistatin transcription in the ovary, through both 89 
forkhead and SMAD elements, provides support for the potential interaction between these elements (24). 90 
In the ovary, function of the FOXL2 protein can be regulated via non-SMAD signaling pathways, as 91 
demonstrated by LATS1 kinase phosphorylation of FOXL2 (25), providing a potential mechanism for 92 
direct FOXL2 protein activation. Understanding whether interaction with SMAD3 is necessary to activate 93 
FOXL2 in the gonadotrope cell or if FOXL2 itself can be activated by activin, such as by LATS1, is of 94 
great interest considering the pathophysiological effects that occur in the presence of disrupted FOXL2 95 
function. 96 
 Various FOXL2 mutations have been identified in patients with Blepharophimosis Ptosis 97 
Epicanthus Inversus Syndrome (BPES). BPES is an autosomal dominant disorder that is characterized by 98 
distinctive eyelid abnormalities that result from mutations in the FOXL2 gene. Two clinical subtypes have 99 
been described and the majority of BPES occurrences are classified Type I, which is associated with 100 
premature ovarian failure (26). In particular, patients with mutations in the FOXL2 gene that lead to a 101 
truncation of the FOXL2 protein are at high risk of developing premature ovarian failure (27). 102 
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Considering that premature ovarian failure is not only associated with mutations of the FOXL2 gene in 103 
BPES patients, but that individuals with this reproductive defect exhibit higher FSH levels in the 104 
circulation (3), it is intriguing to postulate that mutations of FOXL2 that mimic those found in the BPES 105 
patients may underlie the dysregulation of FSHtranscription, as a pituitary contribution to the 106 
development of premature ovarian failure. 107 
 Studies of FOXL2-null mice confirmed a plethora of physiologic problems in vivo (28, 29). In 108 
addition to craniofacial defects, FOXL2-null mice exhibit disruption of granulosa cell differentiation and 109 
fail to form secondary follicles within the ovary. Following these initial studies, two other reports 110 
analyzed the in vivo role of FOXL2 in the pituitary gland. A complete FOXL2-null mouse (30) was 111 
shown to have lower FSH and GSU levels, while LH expression was not affected. Furthermore, both 112 
basal FSH and activin-stimulated FSH secretion were reduced, while neither basal LH, nor GnRH-113 
stimulated LH secretion, were altered. In support of a pituitary role in the reproductive phenotype of the 114 
FOXL2-null mouse, mice with gonadotrope-specific deletion of FOXL2 using GnRH-receptor-mediated 115 
CRE expression, exhibited subfertility and lower FSH levels (31). These initial studies lay the foundation 116 
for investigating the molecular mechanism whereby FOXL2 contributes to maintenance of gonadotropin 117 
gene expression. 118 
 Given the role of FOXL2 in activin induction of FSH, the question remains whether activin can 119 
induce FOXL2 protein itself or whether FOXL2 is activated by protein-protein interaction with SMAD 120 
proteins at the level of the promoter. Several putative FOXL2 sites are found in the proximal FSH 121 
promoter, most with adjacent or overlapping SMAD elements. In this manuscript, we determine which of 122 
these putative forkhead elements are functional FOXL2 sites, and which are not FOXL2 sites, although 123 
they are activin-responsive sites. Furthermore, we demonstrate that SMAD4 proteins and FOXL2 form a 124 
higher-order complex on the most proximal forkhead element, which has the largest effect on activin-125 
responsiveness of the FSH promoter. Interestingly, we show that mutations in FOXL2 that lead to 126 
truncated FOXL2 proteins analogous to those found in BPES, elicit higher induction of the 127 
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FSHpromoterAdditionally, we determine that FOXL2 plays a role in synergistic induction of FSH 128 
reporter activity by GnRH and activin, integrating their pathways at the level of the FSH promoter. 129 
 130 
Materials and Methods 131 
 132 
FOXL2-null mice and timed matings 133 
 The FOXL2-null mice were a generous gift from Louise Bilezikjian at the Salk Institute and have 134 
been previously described (30). Animals were maintained under a 12-hour light, 12-hour dark cycle and 135 
received food and water ad libitum. All experiments were performed with approval from the University of 136 
California San Diego Animal Care and Use Committee and in accordance with the National Institutes of 137 
Health Animal Care and Use Guidelines. Briefly, genomic DNA was extracted from toe biopsies and 138 
analyzed for the presence of the insertion of a Neomycin gene by PCR amplification using primers 139 
specific to FOXL2 and Neo: Neo-forward 5′-CTTGGGTGGAGAGGCTATTC-3′ and Neo-reverse 5′-140 
AGGTGAGATGACAGGAGATC -3′, FOXL2wt-forward 5′-CACGGGAAAGCAGAGGCCGC -3′ and 141 
FOXL2wt-reverse 5′-GGATCTCTGAGTGCCAACGC -3′. Heterozygous males and females were used 142 
for timed mating experiments. Males and females were paired in the afternoon, and the following 143 
morning, females were checked for vaginal plugs with that time designated as e0.5. At the desired stage 144 
of embryonic development, females were sacrificed and embryos harvested. Biopsies of embryos were 145 
taken before embryo fixing and genotype determined. 146 
 147 
Immunohistochemistry 148 
 Embryos were fixed (10% acetic acid, 30% formaldehyde, and 60% ethanol) overnight at 4°C 149 
and dehydrated in ethanol/water washes before embedding in paraffin. Fixed embryos were embedded in 150 
paraffin by the University of California, San Diego, Histology Core. Embedded embryo heads were cut 151 
into 14-μm sagittal sections with a microtome and floated onto SuperFrost Plus slides (Fisher Scientific, 152 
Auburn, Alabama) and dried overnight at room temperature. Slides were incubated at 60°C for 30 153 
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minutes, deparaffinized in xylene washes, and rehydrated in ethanol/water washes. Antigen unmasking 154 
was performed by heating for 10 minutes in a Tris-EDTA-Tween20 mixture. After cooling and washing 2 155 
times in water, endogenous peroxidase was quenched by incubating for 10 minutes in 0.3% hydrogen 156 
peroxide. After washing in phosphate-buffered saline (PBS), slides were blocked in PBS with 5% goat 157 
serum and 0.3% Triton X-100 for 45 minutes, then incubated with primary antibodies against LH, FSH, 158 
GSU, TSH, ACTH, or GH (1:1000, obtained from National Hormone and Peptide Program, NIDDK) in 159 
PBS with 5% serum overnight at 4°C. After washing 3 times in PBS, slides were incubated with 160 
biotinylated goat anti-chicken or goat anti-rabbit IgG (Vector Laboratories) diluted 1:300 in PBS, for 30 161 
minutes, then washed 3 times in PBS. The Vectastain ABC elite kit (Vector Laboratories) was used per 162 
manufacturer's instructions and incubated for 30 minutes. After washing, the VIP peroxidase kit was used 163 
for colorimetric staining for 3 minutes. Slides were dehydrated in an ethyl alcohol series and xylene, then 164 
coverslips were mounted with Vectamount (Vector Laboratories). Sixty-four sections were obtained per 165 
pituitary and stained alternatingly for two hormones.  To quantify the number of gonadotropin subunit-166 
staining cells, five sections per animal were counted from the middle of the pituitary, approximately 50 167 
μm apart. Counting was performed blinded to the genotype, using ImageJ software from NIH, after which 168 
the count and cell delineation were confirmed visually. Statistical differences between genotypes were 169 
determined using a T-test and JMP software (SAS Institute; Cary, North Carolina). 170 
 171 
qPCR analysis of embryo pituitary at e18.5 172 
Adult FOXL2 heterozygous mice were set up in timed matings. On e18.5, the pregnant females 173 
were euthanized and the embryos were extracted. Pituitaries were dissected and placed individually in 174 
tubes on dry ice. The embryos were genotyped from tail biopsies using primers for the Neomycin 175 
selective marker and FOXL2 wild-type gene. The pituitaries were pooled into wild-type and FOXL2-null 176 
groups. Each group contained 5 individual embryonic pituitaries. RNA was isolated from the pituitaries 177 
using a QIAshredder and RNeasy mini kit (QIAGEN Sciences, Germantown, Maryland), as directed by 178 
the manufacturers. Total RNA was reverse transcribed using an iScript cDNA Synthesis kit (Bio-Rad 179 
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Laboratories, Hercules, CA). qPCR was performed using an iQ SYBR Green supermix and an IQ5 real-180 
time PCR machine (Bio-Rad Laboratories, Hercules, CA), with the following primers: LH forward: 181 
CTGTCAACGCAACTCTGG, LH reverse: ACAGGAGGCAAAGCAGC; GAPDH forward: 182 
TGCACCACCAACTGCTTAG, GAPDH reverse: GGATGCAGGGATGATGTTC; FSH forward:  183 
GCCGTTTCTGCATAAGC, FSH reverse: CAATCTTACGGTCTCGTATACC; GSU forward:   184 
ATTCTGGTCATGCTGTCCATGT, GSU reverse: CAGCCCATACACTGGTAGATGG; GH forward: 185 
CCTCAGCAGGATTTTCACCA, GH reverse: CTTGAGGATCTGCCCAACAC; under the following 186 
conditions: 95 C for 15 min, followed by 40 cycles at 95 C for 20 sec, 56 C for 30 sec, and 72 C for 30 187 
sec. Three samples with 5 pooled animals each was assayed. A standard curve with dilutions of 10 188 
pg/well, 1 pg/well, 100 fg/well, and 10 fg/well of a plasmid containing LH, FSH, or GAPDH cDNA, 189 
was generated in each run with the samples. The amount of LH was calculated by comparing threshold 190 
cycle obtained for each sample with the standard curve generated in the same run. Replicates were 191 
averaged and divided by the mean value of GAPDH in the same sample. After each run, a melting curve 192 
analysis was performed to confirm that a single amplicon was generated in each reaction.  193 
 194 
Cell culture and transient transfections 195 
 The expression vectors for SMAD3, SMAD4, and FOXL2 were kindly provided by Drs. J. 196 
Massague (Memorial Sloan-Kettering Cancer Center, New York), D. Bernard (McGill University, 197 
Montréal, Québec, Canada), and L. Bilezikjian (Salk Institute, La Jolla, California), respectively. The 198 
human FOXL2 expression vector and its mutations were a gift from Dr. J. Bae (Pochon CHA University, 199 
Republic of Korea), while LATS1 kinase and its mutant were kindly provided by Dr. M. Pisarska 200 
(UCLA, California). The mouse FSH-luciferase reporter vectors were published previously (7, 32). 201 
Mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 202 
CA) according to the manufacturer’s protocol, using the mouse 1 kb FSH promoter in the pGL3 203 
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luciferase vector as a template. Mutated residues are indicated in Figure 6A. Mutations were confirmed 204 
via dideoxyribonucleotide sequencing. 205 
 LT2 cells were cultured at 37C in DMEM (Cellgro, Mediatech, Inc., Herndon, VA) containing 206 
10% fetal bovine serum (Omega Scientific Inc., Tarzana, CA) and penicillin. Cells were split into 12-well 207 
plates 1 day prior to transfection and transfected using Fugene 6 reagent (Roche Molecular Biochemicals, 208 
Indianapolis, IN) in accordance with the manufacturer’s protocol. Wells were transfected with 500 ng of 209 
FSH-luciferase reporter plasmids, 100 ng of the -galactosidase reporter plasmid driven by the Herpes 210 
virus thymidine kinase promoter to serve as an internal control for transfection efficiency, and 200 ng of 211 
expression vectors, as indicated in the figures and legends. Cells were incubated in serum-free DMEM 212 
containing 0.1% BSA and antibiotics overnight prior to hormone treatment with 10 ng/mL activin 213 
(Calbiochem, La Jolla, CA), or 10 nM GnRH (Sigma). Subsequent to treatment, cells were washed with 214 
1X phosphate buffer saline (PBS) and lysed with 60 L of 0.1 M potassium-phosphate buffer pH 7.8 with 215 
0.2% Triton X-100. A 96-well luminometer plate was loaded with 20 L of each of the lysates and 216 
luciferase activity was measured after injection of a buffer containing 100 mM Tris-HCl with pH 7.8, 15 217 
mM MgSO4, 10 mM ATP, and 65 M luciferin per well, using a Veritas Microplate Luminometer 218 
(Turner Biosystems, Sunnyvale, CA). The Galacto-Light Assay (Tropix, Bedford, MA) was performed 219 
according to the manufacturer’s protocol to measure galactosidase activity. All experiments were 220 
performed a minimum of three times and in triplicates within each experiment. Luciferase values were 221 
normalized to -galactosidase for each sample, relative to empty vector pGL3 luciferase reporter activity. 222 
Statistical significance was determined with analysis of variance (ANOVA) and significance was set at p 223 
< 0.05 represented by an asterisk.  224 
 225 
EMSA 226 
In vitro transcribed and translated FOXL2 and SMAD proteins were synthesized using the TnT 227 
kit from Promega (Coupled Reticulocyte Lysate System, Promega Corporation, Madison, WI) according 228 
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to the manufacturer's instructions. Two hours following activin treatment of LT2 cells, nuclear extracts 229 
were obtained by swelling the cells with hypotonic buffer [20 mM Tris pH 7.4, 10 mM NaCl, 1 mM 230 
MgCl2, 1 mM PMSF, protease inhibitor cocktail (Sigma-Aldrich), 10 mM NaF, 0.5 mM EDTA, 0.1 mM 231 
EGTA]. Cells were broken by passing through a 25
5
/8 G needle, 3 times. Samples were centrifuged at 232 
4000 rpm for 4 min and the nuclear pellets were resuspended in hypertonic buffer [20 mM Hepes pH 7.8, 233 
20% glycerol, 420 mM KCl, 1.5 mM MgCl2, 1 mM PMSF, protease inhibitor cocktail (Sigma-Aldrich), 234 
10 mM NaF, 0.5 mM EDTA, and 0.1 mM EGTA]. Protein determination was performed using the 235 
Bradford reagent (Bio-Rad, Hercules, CA). The following oligonucleotides were used as 30-bp probes, 236 
encompassing the sites of interest: FBE1: AATTAAGACATATTTTGGTTTACCTTCGCA, 202: 237 
CATATCAGATTCGGTTTGTACAGAAACCAT, FBE2: 238 
CTCTGTGGCATTTAGACTGCTTTGGCGAGG, and FBE3: 239 
CTCCCTGTCCGTCTAAACAATGATTCCCTT. Oligonucleotides were annealed and labeled with γ32P 240 
ATP using T4 Polynucleotide Kinase (New England Biolabs, Inc., Beverly, MA). Binding reactions 241 
contained 2 µg of nuclear proteins in a total volume of 20 l containing the following: 10 mM Hepes pH 242 
7.8, 50 mM KCl, 0.5 mM MgCl2, 10% glycerol, 0.1% NP-40, 0.25 µg dIdC, 5 mM DTT, and 5 fmol of 243 
labeled probe. Reactions were loaded onto a 5% nondenaturing polyacrylamide gel and ran in 0.25X Tris-244 
borate-EDTA buffer. Gels were run at 250 V/cm
2
 constant voltage and dried. Autoradiography was 245 
performed to identify complexes. 246 
 247 
Western Blot 248 
Cells were rinsed with 1x PBS and lysed with a buffer containing: 20 mM Tris pH 7.4, 140 mM 249 
NaCl, protease inhibitors (Sigma), 1 mM PMSF, 10 mM NaF, 1% NP-40, 0.5 mM EDTA, and 1 mM 250 
EGTA to obtain whole cell lysates. Nuclear extracts were obtained as described above. Bradford reagent 251 
was used to determine protein concentrations, calculated using a standard curve. Equal amounts of protein 252 
were loaded on the gel, resolved by gel electrophoresis and transferred to a polyvinylidene fluoride 253 
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(PVDF) membrane. The membranes were blocked with 10% milk in wash buffer (20 mM Tris 7.4, .1% 254 
tween, 150 mM NaCl, and 0.5% BSA) and then probed with antibodies to cMYC. Proteins were detected 255 
with an Enhanced Chemiluminescence (ECL) Western Blotting Detection Reagent (GE Healthcare, 256 
Piscataway, NJ). To assure equal loading, membranes were stripped at 60˚C for 1 hour with strip buffer 257 
(50 mM Tris pH 6.8, 5% SDS, and 100 mM β-mercaptoethanol and re-exposed to ECL and 258 
autoradiography to ensure complete removal of the antibody and then blocked again with milk and 259 
reprobed for lamin B or -tubulin. 260 
 261 
GST Interaction Assay 262 
 The Glutathione S-Transferase (GST)-FOXL2 in the pGEX vector was kindly provided by Dr. L. 263 
Bilezikjian. The SMAD3 expression vector was obtained from J. Massague, cJUN from M. Birrer, and 264 
cFOS from Dr. Tulchinsky. 
35
S-labeled proteins were produced using the TnT® T7 Coupled Reticulocyte 265 
Lysate System (Promega Corporation, Madison, WI). Bacteria transformed with the pGEX vectors were 266 
grown to an OD of 0.6, upon which protein expression was induced by addition of 0.25 mM isopropyl--267 
D-thiogalactosidase (IPTG). Bacterial pellets were sonicated in PBS with 5 mM EDTA and 0.1% Triton 268 
X-100, centrifuged and the supernatant was bound to glutathione sepharose beads (Amersham Pharmacia, 269 
Piscataway, NY). Beads were washed 4 times with sonication buffer followed by equilibration in the 270 
binding buffer (below), and split equally between different samples and the control. 
35
S-labeled proteins 271 
were added to the beads and bound for 1 h at 4ºC in 20 mM Hepes (pH 7.8), with 50 mM NaCl, 10 mg/ml 272 
BSA, 0.1% NP-40, and 5 mM DTT. After extensive washing, samples were eluted from the beads by 273 
boiling in Leammli sample buffer and subjected to SDS-PAGE. Afterwards, the gels were dried and 274 
autoradiographed. 275 
 276 
 277 
 278 
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Results 279 
FOXL2 is required for Fshb and Cga gene expression in vivo 280 
 Using the LT2 gonadotrope cell model, we and others have identified FOXL2 as a key player in 281 
activin induction of FSH transcription (13, 15). These findings were followed by confirming the role of 282 
FOXL2 in vivo, using genetically modified mice (30, 31). However, in the first study using whole-body, 283 
germline FOXL2 ablation, the absence of FOXL2 within the ovary may compromise the effects observed 284 
in the pituitary of complete null, adult female mice, due to the lack of steroid feedback. In the second 285 
model, incomplete recombination in the CRE-loxP animals may have resulted in a knock down rather 286 
than complete deletion in the gonadotrope, since the animals maintained some fertility. Based on these 287 
concerns, we analyzed gonadotropin gene expression during the late embryonic stage, i.e., prior to the 288 
influence of steroid feedback. In our initial assessment, we performed immunohistochemistry to detect 289 
gonadotropin hormones in the pituitary of wild-type and FOXL2-null mice at embryonic day 18.5 (e18.5), 290 
the earliest developmental stage that FSH hormone can be detected in the fetal pituitary. LH is present in 291 
the wild-type pituitaries at the ventral surface (Fig. 1A), as shown previously (33). Pituitary glands from 292 
the FOXL2-null mice also exhibited LH staining, but at a lower level than wild-type littermates. 293 
Likewise, FSH-expressing cells were present in wild-type animals, yet, they were undetectable in the null 294 
animals. Meanwhile, GSU-containing cells were present in both wild-type and null mice. Since FOXL2 295 
is specifically expressed in gonadotrope and thyrotrope lineages within the pituitary, we examined TSH 296 
staining and found that TSHcontaining cells are present at the same level in both genotypes, consistent 297 
with a previous report (30). We also examined specification of other pituitary cells that do not express 298 
FOXL2, except for prolactin, which cannot be detected at this stage of development. Growth hormone 299 
(GH) and adrenocorticotropin hormone (ACTH) cells were present equally in both wild-type and FOXL2-300 
null animals. We counted the number of cells per section to quantify differences in gonadotropin hormone 301 
containing cells observed with staining. The number of either LH- or FSH-containing cells were 302 
significantly reduced in the null embryos, while GSU cell numbers were similar in FOXL2-deficient 303 
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mice and wild-type littermates (Fig. 1B), demonstrating a critical role of FOXL2 in gonadotropin 304 
synthesis. 305 
 To determine whether the decrease in gonadotropins is due to lower expression of their genes, we 306 
performed quantitative PCR (qPCR) analysis of the e18.5 pituitaries (Fig. 2). Lhb mRNA in the FOXL2-307 
null pituitary exhibited 74% lower expression compared to wild-type littermates. Expression of Fshb 308 
mRNA was 98% lower in the FOXL2-null pituitary, and the expression of Cga (αGSU) subunit mRNA 309 
was reduced by 55%. The difference in Gnrhr mRNA did not reach statistical significance, although null 310 
animals exhibited 43% lower expression. As expected, Gh mRNA in the pituitary was equivalent in wild-311 
type and null animals. Foxl2 mRNA was below the detection level in the null animals, confirming 312 
deletion in the pituitary gland of FOXL2 knock-out animals. Collectively, these findings identify FOXL2 313 
as an important factor in mature gonadotropin hormone production and focus our attention on the 314 
molecular mechanism whereby FOXL2 mediates gonadotropin gene expression. 315 
 316 
Higher induction of FSH transcription by truncated FOXL2  317 
 FOXL2 protein contains a forkhead domain (FH, Fig. 3A), which is critical for DNA binding, and 318 
an alanine-rich domain (A, Fig. 3A), common to homeodomain proteins. We obtained expression vectors 319 
that contain deletions of the critical FH or A domains and vectors containing several truncations of the 320 
FOXL2 protein that mimic mutations found in the BPES patients (34), and cotransfected each of them 321 
along with a 1kb mouse FSH-luciferase reporter into LT2 cells, to investigate the importance of these 322 
protein domains for activation of FSH gene expression (Fig. 3B). Overexpression of wild-type FOXL2 323 
(WT) induced FSH-luciferase. In contrast, a FOXL2 expression vector with deletion of the forkhead 324 
domain (dFH) failed to significantly induce reporter activity. Surprisingly, deletion of the alanine-rich 325 
domain (dAla) or truncations that mimic mutations in BPES patients (t274 and t218) caused higher 326 
induction of the FSH reporter. Since mutations can alter the expression and the half-life of the protein 327 
and therefore its function, we analyzed the quantity of FOXL2 mutant proteins produced by 328 
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overexpression in LT2 cells using western blotting to detect the cMYC-tag on each of the mutant 329 
proteins (Fig. 3C). -tubulin (-tub, lower image Fig. 3C) served as a loading control. Surprisingly, we 330 
determined that mutations which resulted in higher FSH-luciferase expression were actually expressed at 331 
lower level than the wild-type FOXL2 protein. Given that these mutations may alter nuclear localization 332 
of FOXL2, we also assayed nuclear levels of overexpressed proteins (Fig. 3D) and nucleus-restricted 333 
lamin B served as a loading control in the bottom image. All overexpressed FOXL2 proteins were found 334 
at a similar level in the nucleus. These findings suggest that mutations in the FOXL2 gene, reported in 335 
some BPES patients, may cause a pituitary phenotype (in addition to the ovarian effects), which results in 336 
higher expression of the FSH gene.  337 
 338 
FSHβ promoter elements, FBE1 at -350 and FBE3 at -120, are FOXL2 sites 339 
 Using the LT2 cell model, we previously determined that the distal FOXL2 site plays a role in 340 
activin induction of FSHβ, but not in the basal expression of this gene (15). However, FOXL2 binding to 341 
this site in the FSHβ promoter is not different between nuclear extracts from LβT2 cells with or without 342 
activin treatment (15) and it is not clear how activin activates the FOXL2 protein to induce FSHβ 343 
transcription. We could not detect a change in FOXL2 migration following activin treatment using high 344 
resolution western blots, which would have indicated the possibility of post-translational modification 345 
(data not shown). In the ovary, FOXL2 plays a role in granulosa cell gene expression and is activated by 346 
phosphorylation by LATS1 kinase (25). In the gonadotrope, however, overexpression of LATS1 or its 347 
dominant-negative mutant did not affect activin induction of the FSH reporter (data not shown). As an 348 
alternative approach, we performed a detailed analysis of FOXL2-binding sites present in the mouse 349 
FSH promoter, since FOXL2 may be activated by protein-protein interaction at the DNA level.   350 
 There are four putative FOXL2 binding sites in the mouse FSHβ promoter (Fig. 4A), three that 351 
we identified in Corpuz, et al. [-350, -206 and -155; (15)], and one identified by Lamba, et al. [-114, 352 
(13)]. In a later publication, Tran, et al. (20), named the -350 site FBE1, the -155 site FBE2, and the -114 353 
  Roybal, et al. 
 15 
site FBE3, and for ease of comparison, we will employ the same nomenclature, and retain the numbering 354 
for the -206 site only, which that study (20) did not analyze. We compared all of these sites in parallel, 355 
using mutations of the residues underlined in Fig. 4A to determine the contribution of each site in activin 356 
and FOXL2 induction of the FSHβ promoter. Each individual mutation significantly lowered induction by 357 
activin, suggesting that each of these sites plays a role in activin induction of FSHβ-luciferase (Fig. 4B). 358 
To determine which of these function as FOXL2 responsive sites, we overexpressed FOXL2, using an 359 
expression vector, together with a reporter containing the wild-type FSH promoter or individual FSH 360 
reporters containing these selective mutations in the putative FOXL2 sites. Mutation of either FBE1 (-350 361 
site) or FBE3 (-114 site) lowered the induction by FOXL2 compared to the induction of the wild-type 362 
reporter (Fig. 4C), implicating these sites as critical for specific regulation by FOXL2. The other two 363 
sites, FBE2 and -206, may involve different activin-regulated transcription factors, as mutation in these 364 
sites did not alter the ability of FOXL2 to induce FSH-luciferase expression.  365 
 We compared the binding of FOXL2 to its putative sites using EMSA. Using control and activin-366 
treated nuclear extracts from LT2 cells, gel shift assays showed that FOXL2 binds to FBE1 and FBE3, 367 
but not to FBE2 and -206 (Fig. 5A; C, control; A, activin; L2, FOXL2 antibody; Ig, IgG control 368 
antibody; and data not shown). We previously determined that FBE3 is proximal to the Pbx/Prep complex 369 
binding site (35), and that these proteins can be seen binding to FBE3 in LβT2 nuclear extracts (Fig. 5A). 370 
Therefore, to eliminate the influence of potential protein-protein interaction through which FOXL2 may 371 
be recruited to the promoter, and to analyze binding of only FOXL2 protein to DNA, in vitro translated 372 
and transcribed FOXL2 protein was also utilized and showed similar results (Fig. 5B, V, vector control; 373 
F, FOXL2 expression vector). Thus, FOXL2 binds FBE1 and FBE3 and mutation of these sites decreases 374 
induction by FOXL2, while the FBE2 and -206 site mutations do not affect induction by FOXL2, 375 
suggesting that these sites are not functional FOXL2 sites, but may bind different activin-regulated 376 
proteins. 377 
 378 
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FBE3 requires both the SMAD and FOXL2 elements 379 
 Due to the possibility that FOXL2 binding may be affected by protein-protein interaction while 380 
bound to DNA, we performed a detailed analysis of the FOXL2 binding sites present in the mouse FSH 381 
promoter. The FBE2 and FBE3 sites were originally identified as activin-responsive elements due to 382 
encompassing a SMAD element, AGAC or GTCT (dashed underline in the wild-type sequence for each 383 
site; Fig. 6A) (35). Contained within each of the FBE2 and FBE3 sites is a SMAD element, which 384 
overlaps the binding site for FOXL2, a forkhead element: CTAAACAC (solid underline). Unintentionally 385 
hindering our ability to distinguish between actions through either site, our original publication describing 386 
the FBE2 and FBE3 sites (35) established their role in activin induction using specific 2-base-pair 387 
mutations of the overlapping two residues shared by the SMAD and forkhead sites ("FBE2 both" and 388 
"FBE3 both", mutations in both the SMAD and forkhead elements; Fig. 6A). FBE1, the -350 FOXL2 site 389 
(solid line), was identified with truncation/mutation analysis (15), and it also is juxtaposed to a SMAD 390 
site (dashed underline). Since the mechanisms of activation of FOXL2 by activin signaling remain 391 
unclear, yet SMAD activation is considered a prototypical phosphorylation target of the activin receptor 392 
serine/threonine kinase, we asked whether elements for either of these proteins contribute to activin 393 
induction of the FSH promoter. For the sake of completeness, we also analyzed the -206 site, since the 394 
putative -206 site was identified using in silico analysis. Furthermore, the original report (15) assessed 395 
whether the double mutation (db), mutating both T repeats, affected activin induction of FSH [Fig. 4B, 396 
and (15)]. Here, we created two separate mutations in the -206 element: 206 fh that encompasses 397 
mutations of the T repeat in the forkhead element, and 206 x that mutates the two T residues 5' of the 398 
forkhead element. For the three FBE sites, we created mutations specifically in the SMAD sites (sm) or 399 
forkhead elements (fh), in addition to double (db) mutations for FBE1, and single mutations in the 400 
overlapping FOXL2 and SMAD elements that affect both elements (both), for FBE2 and FBE3 (Fig. 6A).  401 
 Basal expression was lower with all three mutations in the most proximal FBE3 site, while other 402 
mutations did not significantly affect basal expression of the reporter (Fig. 6B). To analyze the effect of 403 
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activin, FOXL2 or SMAD proteins, we present data as fold induction (Fig 6C-G), in which each reporter 404 
treated with activin or with overexpressed proteins, is normalized to its own vehicle-treated or empty 405 
expression vector control, which takes into account these changes in basal expression. Induction by 406 
activin was reduced by 41% with mutation of the -350 forkhead element, FBE1 fh, but not with mutation 407 
of the adjacent SMAD site, FBE1 sm (Fig. 6C). The double mutation of the SMAD and forkhead sites, 408 
FBE1 db, had the same effect as mutation of the forkhead element alone, indicating that the adjacent 409 
SMAD site is not functional. Surprisingly, mutation of the -206 forkhead element, 206 fh, did not reduce 410 
FSHβ induction, but the mutation 5' to it, 206 x, reduced activin induction by 73%, to the same level as 411 
double mutation, 206 db (Fig. 6C). This result, combined with the gel shift assays, strongly indicates that 412 
-206 is not a FOXL2 site. As reported previously, mutation of the FBE2 element that affected both the 413 
SMAD and FOXL2 sites (FBE2 both) diminished activin induction by 74%. Unexpectedly, mutation in 414 
either the SMAD (FBE2 sm) or FOXL2 (FBE2 fh) elements alone did not significantly lower activin 415 
induction, implying that FBE2 is neither a SMAD, nor FOXL2 site, and activin responsiveness is 416 
conferred by a presently unidentified protein that requires the residues mutated in the "both" mutant. Any 417 
mutation of the FBE3 site that affected either the SMAD (FBE3 sb) or FOXL2 elements (FBE3 fh) or the 418 
two elements together (FBE3 both) eliminated induction by activin. Collectively, our findings are 419 
consistent with previous data (Fig. 4B) (13, 15), indicating that the FBE1 and FBE3 sites are critical for 420 
activin responsiveness of the FSH promoter. Moreover, these results show that -206 and FBE2 are not 421 
FOXL2 sites, although they are critical for activin responsiveness through, as of yet, unidentified proteins. 422 
 The same mutations were used to assess the contribution of each site to overall induction by 423 
FOXL2. Wild-type FOXL2 protein was overexpressed with these reporters and established that the base 424 
pairs mutated in FBE1 db, FBE1 fh, FBE3 both, and FBE3 fh all play roles in induction by FOXL2 (Fig. 425 
6D), since mutation of these sites lowered induction by half. However, the adjacent and overlapping 426 
SMAD sites in FBE1 and FBE3 do not play roles in induction by FOXL2, and, as shown previously (Fig. 427 
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4C), neither do -206 or FBE2. Thus, FOXL2 induces FSH through the FBE1 and FBE3 forkhead 428 
elements. 429 
 SMAD3, which is a major effector of activin signaling in the induction of FSH, was 430 
overexpressed with these mutant reporters, to determine the roles of these sites in SMAD3 induction of 431 
FSH (Fig. 6E). As reported previously, the mutation FBE1 fh reduced SMAD3 induction by 66%, while 432 
mutation of the adjacent SMAD site had a minor effect. Thus, the FBE1 FOXL2 site plays a role in 433 
SMAD3 induction, presumably by recruiting SMAD3 to the promoter through a FOXL2-SMAD3 434 
interaction (18). Surprisingly, the 206 fh mutation did not have an effect, while the 206 x mutation 435 
reduced SMAD3 induction by 67%, as did the double (206 db) mutation. Thus, 206 fh does not contribute 436 
to activin, FOXL2 or SMAD3 induction of FSH, while the 206 x element contributes to the activin and 437 
SMAD3 induction, which again may indicate that another, as yet unidentified, factor, which may interact 438 
with SMADs, binds to this sequence. Similar to activin induction of the FBE2 mutations, SMAD3 439 
induction was reduced with the mutation of both elements (FBE2 both) by 64%, while mutations of the 440 
individual elements, sm and fh, did not have an effect. This again points out that SMAD3 may function in 441 
cooperation with an as yet unidentified protein through protein-protein interaction at the FBE2 site. As 442 
with activin, within the FBE3 site, both the forkhead and the SMAD elements play roles in SMAD3 443 
induction of FSH-luciferase. Mutation of either of these elements diminished the induction by SMAD3, 444 
indicating that this site, encompassing both SMAD and forkhead elements, is critical for FSH regulation. 445 
Similar results were obtained with overexpression of the SMAD3 binding partner, SMAD4, with one 446 
interesting exception (Fig. 6F). SMAD-specific mutation of the FBE2 site lowered induction by SMAD4, 447 
but not by SMAD3. This indicates that the putative protein binding to the FBE2 contributes to activin 448 
induction of the promoter through interaction specifically with SMAD4, which may bind the SMAD-449 
binding site, while SMAD3 may be recruited through protein-protein interaction. Induction by co-450 
expression of SMAD4 and FOXL2 (Fig. 6G), SMAD3 and FOXL2 or all three proteins (data not shown) 451 
was lowered by the double mutation of FBE1, but not the single mutation, indicating that both sites were 452 
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necessary for synergistic induction by SMADs and FOXL2. Induction of FSH reporter was also lowered 453 
by the FBE2 both mutation and all of the mutations of the FBE3, again indicating the critical role of these 454 
sites. 455 
 To further examine whether SMADs, known to interact with FOXL2, can form complexes on the 456 
FBE sites, we included increasing amounts of overexpressed SMAD3, SMAD4, or SMAD3+4 with 457 
FOXL2 and analyzed their binding in gel shift assays. As stated previously, we were unable to detect 458 
FOXL2 or SMAD3 binding to either the -206 site or the FBE2, so we analyzed two 30 base-pair probes 459 
encompassing either the FBE1 (Fig. 7A) or the FBE3 (Fig. 7B) site. We demonstrate that FOXL2 alone 460 
binds either the FBE1 or FBE3 site, but SMAD proteins alone do not bind either site (Fig. 7A). SMAD3 461 
is recruited to either the FBE1 or FBE3 site in the presence of FOXL2. In contrast, SMAD4 protein is 462 
recruited to only the FBE3 in the presence of FOXL2, but not FBE1, and results in formation of a high-463 
order complex (Fig. 7A and 7B). This higher order complex formed only on the wild-type promoter, and 464 
was not observed when mutations of either the SMAD or FOXL2 sites were introduced into the probe 465 
(data not shown). Whether or not SMAD proteins are also binding DNA directly or only being recruited 466 
to the complex by FOXL2 cannot be distinguished here. Collectively, our data indicate that FOXL2 and 467 
SMAD4 proteins can form a complex only on the FBE3 site and this interaction may explain why the 468 
FBE3 mutation has a larger effect on activin induction of FSH compared to mutation of the FBE1. 469 
 470 
FOXL2 contributes to synergistic induction of FSH by activin and GnRH 471 
 Previously, we reported that activin and GnRH cause synergistic activation of FSH transcription 472 
(an induction that is higher than additive induction by each hormone alone). Indeed, the finding that 473 
endogenous activin is necessary for maximal induction by GnRH (7), provides another piece of evidence 474 
supporting this synergy, which may be critical for differential regulation of gonadotropin subunits. Here, 475 
we analyzed the FBE sites to investigate additional mechanisms underlying synergistic induction by 476 
GnRH. The 206 db, the 206 x, and the FBE3 both mutation, lowered induction by GnRH by 25%, 24%, 477 
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and 27%, respectively (Fig. 8A). Synergy was reduced by mutation of the same sites that lowered activin 478 
induction (compare Figures 6B and 8B), and, additionally, by mutation of the FBE2 fh forkhead element 479 
that did not have a role in activin induction alone (Fig. 7B). Although FBE1 fh, FBE2 both, FBE3 fh, and 480 
FBE3 sm played roles in both activin induction and synergy, they did not contribute to the induction by 481 
GnRH alone. Together, these data indicate that there is site specificity for activin, GnRH, and synergistic 482 
responsiveness.  483 
 To determine the contribution of the FOXL2 protein to the synergistic effect of activin and 484 
GnRH, we overexpressed a dominant-negative (dn) FOXL2 protein that contains a deletion in the 485 
forkhead domain (18, 36). Overexpression of the dn FOXL2 reduced basal expression of the FSHβ 486 
reporter by 25% (Fig. 8C), as well as induction by hormone treatments. It also lowered fold induction by 487 
hormones, which is presented for clarity in the bracketed part of the Fig. 8C, when induction by the 488 
hormone was normalized to the reduction in basal expression. Fold induction by GnRH was lowered by 489 
35%, activin by 28%, and synergy by 45%. Thus, functional FOXL2 protein is necessary for FSH 490 
induction by GnRH, activin and the synergy between the two hormones.  491 
We examined the mechanism by which FOXL2 contributes to synergy between GnRH and 492 
activin by analyzing whether FOXL2 protein can interact with cJUN or cFOS, immediate early proteins 493 
induced by GnRH that act to increase FSH transcription (32). Alternatively, the role of SMADs may be 494 
to form a bridge between FOXL2 and the cJUN/cFOS AP1 complex, since SMAD3, which is activated 495 
by activin to induce FSH(37), can interact with both cJUN (38) and FOXL2 (18). To differentiate 496 
between these two hypotheses, we performed GST pull-down assays in which in vitro transcribed and 497 
translated cFOS and cJUN proteins were tested for protein-protein interaction with a FOXL2-GST fusion 498 
protein. SMAD3 was included as a positive control. In this assay, cJUN interacts with the FOXL2 protein 499 
(Fig. 9, middle panel). S
35
-labeled cJUN, but not cFOS, precipitated with glutathione beads through an 500 
interaction with GST-FOXL2. No interactions were observed using GST alone, indicating specificity of 501 
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this binding (Fig. 9, right panel). Thus, FOXL2 and cJUN form heteromeric complexes in vitro, through 502 
direct protein-protein interaction without the need for SMAD3. 503 
 504 
 505 
Discussion 506 
 In this study, we determined that functional FOXL2 is necessary for FSH hormone synthesis and 507 
LH, FSH and GSU gene expression in the pituitary during the late stage of fetal development. 508 
Furthermore, we have substantially extended understanding of the molecular mechanisms of FOXL2 509 
function by identifying critical elements necessary for DNA binding and transcriptional activation, and 510 
demonstrating that FOXL2 contributes to synergistic induction of FSHby GnRH and activin. 511 
 FOXL2 is a member of the forkhead family of transcription factors (16) that has important roles 512 
in reproductive function. In the human population, BPES is caused by mutations in the FOXL2 gene. One 513 
manifestation of BPES is premature ovarian failure, strongly implicating FOXL2 in female reproductive 514 
fitness (26). FOXL2-null mice exhibit reproductive defects including disruption of granulosa cell 515 
differentiation and failure of follicle growth (29). FOXL2 exhibits cell-specific expression in the pituitary, 516 
where it is restricted to cells of the gonadotrope and thyrotrope lineages and colocalizes with FSH (17, 517 
18). Thus, we postulate that the reproductive effects of these mutations could be due to pituitary as well as 518 
ovarian effects. Indeed, previous reports investigating FOXL2 in vivo illustrated that 3-4 week-old 519 
FOXL2-null mice have lower levels of FSH, GSU, GnRH receptor, and GH, but not LH(30). In our 520 
analysis at e18.5, FOXL2-null mice had lower levels of LH, FSHand GSU, but not TSH, GH, or 521 
ACTH, and the difference in GnRH receptor expression did not reach significance. Lack of an effect on 522 
GH or ACTH expression is not surprising, given that FOXL2 expression is limited to the gonadotrope and 523 
thyrotrope lineages. The difference in GH expression that Justice, et al. (30), observed, may manifest later 524 
in development due to the reported decrease in the size of the null pituitary that would be expected to 525 
affect somatotropes disproportionally, as this endocrine cell type is the most abundant within the anterior 526 
  Roybal, et al. 
 22 
pituitary. In contrast to this previous report, we demonstrate a decrease in LH expression, which may 527 
stem from a developmental delay that is resolved by the age of animals studied in Justice, et al. (30), or 528 
reflects the possibility that the LH gene is a target of FOXL2. Activin does regulate LH, although to a 529 
lesser extent than FSH (39-41). Whether this reflects a developmentally dependent action of FOXL2 on 530 
LH remains an intriguing question. In agreement with the previous report, GSU was expressed at a 531 
lower level, supporting a role for FOXL2 in its expression. Consistent with the fact that GSU is 532 
expressed at a relatively high basal level and its mRNA has a long half-life, there was no difference in the 533 
number of cells containing GSU protein, as observed in the previous report. In the conditional FOXL2 534 
knock-out mouse using GnRH-receptor CRE, only FSH was lower, while the other gonadotrope-specific 535 
genes, LH, GSU, and GnRH receptor were not affected (31). In contrast to the completely null mice 536 
used herein, the unchanged levels of GSU demonstrated in the conditional knock-out mouse likely stem 537 
from GSU expression in the thyrotrope, which was not affected by CRE expression. Different results 538 
regarding the LH expression may again implicate developmental effects of FOXL2. Thus, all of the in 539 
vivo models thus far, regardless of the age of the animals, confirm a role for FOXL2 in FSH expression 540 
and provide a strong rationale for investigating the molecular mechanism of FOXL2 function in the 541 
gonadotrope cell. 542 
 BPES is characterized by eyelid dysplasia in both sexes and premature ovarian failure in females 543 
in a large proportion of affected individuals, which are distinguished as having type I BPES. More than 544 
260 different FOXL2 mutations have been identified since the discovery that the FOXL2 gene is mutated 545 
in BPES in 2001 (42). Several of these mutations were previously tested for functionality in a granulosa 546 
cell line (34). The function of FOXL2 in granulosa cells is to negatively regulate transcriptional activation 547 
of ovarian genes, including several involved in steroidogenesis (22, 34, 43). The FOXL2 mutated proteins 548 
that are found in BPES patients lose the ability to repress these genes (34). However, the role of these 549 
FOXL2 mutations in the pituitary was not examined. Due to dysregulation of steroidogenesis and the 550 
resulting disruption in ovarian feedback which influences pituitary hormone synthesis, it is difficult to 551 
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distinguish direct pituitary effects of FOXL2 in BPES patients. Thus, we employed the immortalized 552 
gonadotrope cell line, LβT2, to examine the role of FOXL2 mutations that mimic those in BPES on FSH 553 
reporter activity. As we showed in the previous manuscript (15), both the mouse and human FSH 554 
promoters, which include activin-responsive sites, are conserved in the proximal 350 base pairs from the 555 
transcriptional start site, and, thus, they are similarly regulated by FOXL2. Although the FOXL2 556 
polyalanine repeat domain expansion is a mutational hotspot, it is found in type II BPES, which is not 557 
associated with premature ovarian failure (27). In this manuscript, we show that deletion of the 558 
polyalanine domain causes higher expression of FSH. It is likely that expansion may have the opposite 559 
effect of deletion. Polyalanine expansion leads to intranuclear aggregation or cytoplasmic mislocalization, 560 
thus preventing transcriptional activity of FOXL2 (42), while deletion may lead to a more functional 561 
protein. The majority of mutations in individuals with type I BPES create premature stop codons in 562 
FOXL2 or cause frameshifts, both resulting in truncated proteins (26, 44). Two of these truncations were 563 
used in our studies and caused higher transcriptional activation of FSHcompared to the wild-type 564 
protein. Thus, the effects of the FOXL2 mutations in BPES type I may also be of pituitary origin, causing 565 
higher FSH expression and higher FSH in the circulation, in addition to the critical role for FOXL2 in 566 
the ovary.  567 
 Several putative FOXL2 binding sites were compared in this study. Of those, FBE1 and FBE3 are 568 
bona fide FOXL2 binding sites, while -206 and FBE2 are likely not. This is surprising, since the mouse 569 
FBE2 is very similar to the porcine homologous element, and this corresponding porcine element has 570 
FOXL2 and SMAD3 binding sites, playing an important role in activin regulation of the porcine promoter 571 
(13, 14). As for the FBE1 at -350 in the mouse promoter, it is a forkhead element that binds FOXL2 and 572 
plays a role in activin, FOXL2, and SMAD induction of the FSH promoter. Although FBE1 binds 573 
FOXL2, as does the FBE3 site, it lacks the ability to bind SMADs and is unaffected by a mutation of the 574 
adjacent SMAD half-site, providing an explanation for its lesser role in activin, FOXL2, and SMAD3/4 575 
induction than FBE3. FBE3 is critical for activin responsiveness of the mouse FSH promoter. It was 576 
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initially identified as a putative SMAD-binding element in the proximity of the Pbx/Prep complex with 577 
which SMADs can interact (35). Lamba, et al. (13), and Tran, et al. (20), determined that FOXL2 binds to 578 
this site to induce the murine FSH, and that either SMAD3 or SMAD4, and FOXL2 proteins 579 
synergistically induce FSH through this element. In this report, we determine that both FOXL2 and 580 
SMAD binding elements are required for induction. Of further significance, we determine that FOXL2 581 
and SMAD4 form a higher order complex specifically on FBE3. Since we did not detect SMAD proteins 582 
binding alone to this site, our data indicate that SMAD4 can be recruited to the FBE3 through FOXL2-583 
SMAD protein-protein interaction, and that the SMAD-binding site may contribute to the functional 584 
cooperation between these proteins. 585 
 Two other sites that contribute to activin responsiveness of the FSH gene examined in this 586 
study, -206 and FBE2, do not bind FOXL2 or play a role in FOXL2 induction of FSH. The forkhead 587 
element at the -206 site was identified with in silico analysis (15) and was thought to contain two 588 
overlapping repeats to accommodate binding of a FOXL2 dimer (13). In this report, we created separate 589 
mutations in these two regions and determined that the 3' region that corresponds to the forkhead element 590 
(named 206 fh), does not contribute to activin, FOXL2, SMAD3, or SMAD4 induction of the mouse 591 
FSH promoter, while the 5' region (named 206 x), contributes to activin, SMAD3, and SMAD4, but not 592 
FOXL2, induction. We speculate that a different, as yet unidentified factor, binds to the 206 x site. 593 
Indeed, this site is homologous to the LHX3 site in the human FSH promoter (45, 46). We determined 594 
that LHX3 does not bind the mouse FSHβ promoter in this region (data not shown), but it remains a 595 
possibility that a different Lim protein plays a role in mouse FSH expression. Since this site has a role in 596 
GnRH induction as well, it is intriguing to examine Lim proteins for a possible role in activin, GnRH, and 597 
their synergy on FSHβ. The FBE2 site within the mouse promoter, although homologous to a high 598 
affinity FOXL2 site in the porcine promoter (13), binds FOXL2 with a very low affinity (15). The 599 
overlapping SMAD/Forkhead residues contributed to activin, SMAD3, and SMAD4 induction, but 600 
mutations of the individual elements, FBE2 sm and FBE2 fh, did not contribute to activin or SMAD3 601 
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induction. Surprisingly, mutation of the SMAD element contributes to induction by SMAD4. As with the 602 
206 x site, this may mean that a different protein is involved in activin regulation of the mouse gene 603 
through this element, since we were not able to detect binding of either FOXL2 or SMAD3 to this site 604 
and it is unlikely that these proteins form a complex that requires only overlapping residues. This protein 605 
may interact with SMAD4, however. Further experiments are needed to identify new activin-regulated 606 
factors that function through these two elements in the FSH promoter. 607 
 GnRH and activin synergize to induce FSH. This synergy is specific for FSH and may be one 608 
mechanism of differential regulation of gonadotropin genes (7, 47). We determined previously that there 609 
is both cross-talk between GnRH and activin signaling pathways and interaction between activin-610 
activated SMAD3 and GnRH-induced AP1 on the FSH promoter (7). Due to the role of FOXL2 in 611 
activin induction of the mouse FSH promoter and its interaction and complex formation with SMADs, 612 
we examined whether forkhead elements play a role in GnRH and activin synergy. The sole forkhead site 613 
that plays a role in GnRH induction, likely through a necessity for endogenous activin for maximal GnRH 614 
induction (7), is FBE3, the same site where FOXL2 and SMADs form a complex. The other site that 615 
contributes to GnRH induction is 206 x, which may bind an unidentified protein, as discussed above. Not 616 
surprisingly, other sites that are important for activin induction are also important for synergy. 617 
Additionally, functional FOXL2 protein is necessary for maximal GnRH induction and synergy, since 618 
introduction of a dominant-negative FOXL2 decreases the expression. This likely occurs by disrupting the 619 
function of endogenous FOXL2, since FOXL2 forms a homodimer (13). Interestingly, FOXL2 can 620 
directly interact with cJUN, and this interaction may contribute to the GnRH-activin crosstalk, in addition 621 
to SMAD3 interaction with both cJUN and FOXL2. Thus, FOXL2 may be a part of a transcriptionally 622 
active complex that specifically regulates FSH. 623 
In summary, we have shown that FOXL2 is required for gonadotropin gene expression in vivo 624 
and for synergistic induction of FSH by GnRH and activin. Of multiple forkhead elements, we identify 625 
the most proximal site as the site most important for SMAD and FOXL2 complex formation. 626 
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Additionally, we show that truncated FOXL2 proteins cause higher induction of FSH, while the 627 
forkhead element is necessary for FOXL2 function. Further studies are needed to establish whether these 628 
truncated FOXL2 proteins that cause higher FSH promoter activity, have higher affinity for interacting 629 
SMADs, resulting in either enhanced activin responsiveness, or increased recruitment of basal 630 
transcriptional machinery to the FSH promoter. Further experiments will also aim to determine the 631 
identity of activin-responsive proteins that function through the -206 and FBE2 sites. 632 
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Figure Legends 768 
Figure 1. FOXL2 is necessary for FSH gene expression in vivo. A, Immunohistochemistry of sectioned 769 
pituitary glands collected from wild-type (WT) and FOXL2-null mice (KO) at embryonic 18.5 (e18.5) for 770 
luteinizing hormone (LH), follicle-stimulating hormone (FSH), common -subunit GSU, growth 771 
hormone (GH), thyroid-stimulating hormone (TSH), and adrenocorticotropin (ACTH) with antibodies 772 
obtained from National Hormone and Peptide program, reveals reduced level of gonadotropin hormones 773 
in FOXL2-null mice. B, To determine cell numbers, five sections per animal and three animals per group 774 
were counted and the difference in cell numbers between genotypes was analyzed by T-test.  775 
 776 
Figure 2. FOXL2-null mice have lower expression of gonadotrope-specific mRNAs. Quantitative 777 
PCR of e18.5 pituitaries shows that gonadotropin gene expression is significantly reduced in FOXL2-null 778 
mice. Total RNA was purified from 3 samples per WT or KO group, each with 5 pooled pituitaries, 779 
reverse transcribed, and the level of hormone expression assayed by real-time PCR. In each sample, the 780 
amount of hormone mRNA, calculated from the standard curve, was compared to the amount of Gapdh, 781 
and presented as a ratio. Asterisks * indicate significant difference in the expression in the FOXL2-null 782 
animals from the wild type animals. 783 
 784 
Figure 3. Higher induction of FSH by C-terminal truncations of the FOXL2 protein. Human 785 
FOXL2 was overexpressed with the mouse FSH-luciferase reporter in LT2 cells. A, Schematic 786 
presentation of the FOXL2 protein and its functional domains, forkhead domain (FH) and alanine-rich 787 
domain (A). The numbers above the bar represent residues after which truncations used in B were made, 788 
while numbers below the bar show domain positions. B, Induction of the reporter by each FOXL2 789 
mutation was compared to the induction by the wild-type FOXL2: deletions of the two domains found in 790 
the FOXL2 protein, forkhead domain (dFH), and alanine-rich domain (dAla); and truncations, t274 and 791 
t218, which mimic mutations that occur in BPES patients due to insertion of premature stop codons. 792 
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Asterisks (*) indicate significant induction of the reporter by FOXL2, as determined by one-way ANOVA 793 
followed by Tukey’s posthoc test, while a pound sign (#) indicates a significant increase in induction 794 
compared to the wild-type FOXL2. C, Whole cell lysates were obtained from LT2 cells transfected with 795 
the same MYC-tagged FOXL2 expression vectors as in B, and western blots performed with anti-MYC-796 
tag to analyze the amount of FOXL2 protein. -tubulin (-tub) serves as a loading control. D, Western 797 
blot of the nuclear lysate was performed to determine nuclear localization of various mutations. Nuclear 798 
lamin B1 serves as a loading control presented at the bottom panel.  799 
 800 
Figure 4. FBE1 and FBE3 are FOXL2 responsive sites. A, Schematic presentation of the putative 801 
FOXL2 sites, whose 5' location is indicated with the number below the bar. Sequence for each site is 802 
listed and mutated residues indicated with an underline. Mouse FSH promoter mutations in the putative 803 
FOXL2 sites (illustrated in A), were tested for their responsiveness to activin treatment (B) and FOXL2 804 
overexpression (C) and compared to the wild-type reporter. B, Following transfection of the wild-type 805 
(WT) 1 kb FSH reporter or a reporter containing mutation listed below the corresponding bars, LT2 806 
cells were treated with 10 ng/ml activin or vehicle control for 5 hours. The results are presented as fold 807 
induction, i.e., for each reporter. Activin treatment was normalized to vehicle control to account for 808 
changes in basal expression. *, indicates a significant decrease in fold induction in the mutant reporter 809 
compared to the wild-type. C, Mouse FOXL2 was overexpressed with wild-type or mutant FSH 810 
reporters. * indicates a statistically significant decrease in fold induction when induction by FOXL2 was 811 
normalized to empty vector control for each reporter.  812 
 813 
Figure 5. FBE1 and FBE3 bind FOXL2. EMSA was used to analyze the binding of FOXL2 to elements 814 
FBE1 and FBE3, which contribute to the induction by FOXL2. A, EMSA with nuclear extracts using 30 815 
bp probes that encompass FBE1 and FBE3. "C" above the lanes designates extracts from control, vehicle-816 
treated LT2 cells, while "A" designates 2-hour activin treatment. Antibodies to FOXL2 "L2" were 817 
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included in the binding reaction to identify FOXL2 containing complex (supershift, ss), and specificity 818 
determined by comparison to non-specific IgG antibody (Ig). B, EMSA with in vitro transcribed and 819 
translated vector control (V) and FOXL2 (F) with 30 bp probes that encompass FBE1 or FBE3.  820 
 821 
Figure 6. The role of FOXL2 binding sites in FSH induction. A, To delineate critical elements within 822 
the individual FOXL2 sites, several separate mutations were created in the 1 kb mouse FSH-luciferase 823 
reporter. Forkhead elements are indicated with a solid underline while adjacent SMAD sites are 824 
delineated with the dashed underline on the wild-type sequence. Mutations are listed below and residues 825 
that differ from wild-type sequence illustrated with lower case letters. db, indicates double mutations; sm, 826 
mutation in a SMAD element; fh, mutation in a forkhead element; and, both, mutation in the overlapping 827 
sequence that affects both the SMAD and FOXL2 binding sites. B, Basal expression of the mutants was 828 
compared to the basal expression of the wild-type reporter; * indicates statistically significant difference 829 
as determined by ANOVA and Tukey’s posthoc test. C, LT2 cells were transfected with various 830 
reporters were treated with vehicle or activin for 5 hours, as described in Figure 4. Fold induction by 831 
activin over vehicle-treated control for each reporter is presented and * indicates significantly lower 832 
induction of the mutant compared to the wild type. D, Mouse FOXL2 or vector control were 833 
overexpressed with each reporter. * indicates decrease in fold induction by FOXL2 of the mutant reporter 834 
compared to the wild-type. E, F, G, SMAD3, SMAD4, and a combination of SMAD4 and FOXL2, 835 
respectively, or their vector control, were overexpressed in the same manner. 836 
 837 
Figure 7. FOXL2 and SMAD proteins form complexes on FBE3. A, and B, Using FBE1 (A) or FBE3 838 
(B) as probes in a gel shift, increasing amounts of in vitro transcribed and translated SMAD3 (S3) or 839 
SMAD4 (S4), or both (S3+S4), were incubated with in vitro transcribed and translated FOXL2 to show 840 
the appearance of a complex binding FBE3 that is not present with SMAD protein alone. C, probe only; 841 
F, FOXL2.  842 
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 843 
Figure 8. FOXL2 sites and functional FOXL2 protein are necessary for synergistic induction of 844 
FSH by GnRH and activin. Following transfection with reporters listed in Figure 6, LT2 cells were 845 
treated with 10 nM GnRH (A), or activin and GnRH cotreatment (B), and the induction of the reporter 846 
was analyzed. Results represent fold induction for each reporter and * indicates statistically significant 847 
reduction in induction of the mutant reporter compared to the wild type. C, Dominant-negative (dn) 848 
FOXL2 or its control vector were overexpressed with the FSH-luciferase reporter then cells treated with 849 
GnRH, activin, or both for 5 hours. Expression of the dn FOXL2 protein was confirmed by Western blot 850 
(data not shown). The results are normalized to control vehicle treated cells and * indicates significant 851 
reduction in the induction of the reporter co-expressed with the dn FOXL2 compared to empty vector 852 
control. On the right site, delineated with the dashed line, are the same results with dn FOXL2, this time 853 
presented as fold induction, for easier observation of the changes in induction by hormone. 854 
 855 
Figure 9. FOXL2 interacts with cJUN and SMAD3. S
35 
labeled
 
proteins, SMAD3, cJUN or cFOS, 856 
indicated above the corresponding lanes over the panels, were used in a binding assay with FOXL2-GST 857 
fusion protein (middle panel). In the left panel, 1/10 of protein used in the GST pulldowns was run as 858 
input control to monitor for the migration of each protein. In the right panel, proteins were incubated with 859 
GST alone to confirm the specificity of the interaction. GST proteins were induced with IPTG overnight 860 
and the bacterial pellets were sonicated. These proteins were bound to Glutathione Sepharose beads and 861 
incubated with in vitro transcribed and translated labeled proteins. After extensive washing, the SMAD3 862 
and cJUN are retained in the precipitate through interaction with FOXL2-GST that was visualized after 863 
running on a gel and autoradiography. The experiment was repeated three times with the same results and 864 
a representative experiment is shown. 865 
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